Top GLP-1 & Obesity Drug Stocks
Obesity affects over 1 billion people globally, yet effective pharmacological treatment barely existed before GLP-1 drugs. Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) have demonstrated not just weight loss but cardiovascular, kidney, and liver benefits — expanding their use far beyond initial indications. The GLP-1 market is projected to reach $150B+ by 2030.
Eli Lilly's tirzepatide (Mounjaro/Zepbound) is the most effective approved GLP-1 drug by weight loss magnitude. Lilly is investing aggressively in manufacturing capacity to meet demand that significantly exceeds supply.
Strong price momentum (+47% over 1Y), a top-tier AI score (75), and moderate upside to target (+10%).
Novo Nordisk invented semaglutide (Ozempic/Wegovy) and generated over $25B from GLP-1 products in 2024. Its SELECT cardiovascular outcome trial results position Wegovy for broad cardiometabolic use beyond weight loss.
A below-average AI score (38).
Amgen's MariTide (AMG133) is a monthly injectable GLP-1/GIPR antagonist with differentiated monthly dosing. Phase 3 data could confirm it as a meaningful GLP-1 market entrant.
Solid 1-year momentum (+20%) and attractive valuation (14x forward P/E), though a below-average AI score (47) and limited near-term upside (+5% to target).
AbbVie has an oral GLP-1 (AZD5004 partner candidate) and a broad cardiometabolic pipeline. Its diversified revenue base reduces single-drug concentration risk while providing GLP-1 optionality.
Solid 1-year momentum (+20%), moderate upside to target (+16%), and attractive valuation (13x forward P/E).
Regeneron is developing bispecific antibodies targeting obesity-related pathways. Its strong R&D capability and Sanofi partnership give it resources to compete in the metabolic disease space.
Solid 1-year momentum (+29%) and the highest analyst upside in the group (+36% to target), though a below-average AI score (42).
Moderna is applying its mRNA platform to metabolic diseases including obesity and cardiovascular conditions. Early-stage, but the platform applicability to GLP-1 targets is a longer-term catalyst.
Strong price momentum (+73% over 1Y) and fast revenue growth (+260% YoY), though a below-average AI score (42) and analyst targets below the current price (-8%).
Continuous glucose monitors from Dexcom are standard-of-care for patients on GLP-1 therapies. As GLP-1 adoption expands, CGM penetration grows in tandem — making Dexcom a high-purity infrastructure play.
Moderate upside to target (+12%), though weak 1-year momentum (-16%).
Danaher's bioprocessing equipment (Cytiva) is essential for manufacturing GLP-1 biologics at scale. As Lilly and Novo Nordisk race to expand capacity, Danaher is a key equipment supplier.
Strong upside potential (+34% to analyst target).
- GLP-1 cardiovascular and kidney benefits drive broad label expansions beyond obesity
- Oral GLP-1 drugs (Lilly, Novo, others) dramatically expand the addressable patient population
- Emerging markets (China, India) begin GLP-1 adoption, adding billions to total addressable market
- Supply constraints ease by 2026-27, allowing prescription volumes to finally match latent demand
- Discontinuation rates remain high as patients stop taking GLP-1s due to side effects or cost
- Insurance coverage gaps limit US penetration despite massive demand and awareness
- Generic or biosimilar entry for semaglutide creates pricing pressure earlier than expected
- Next-generation oral GLP-1 competition from multiple entrants commoditizes the category
- LLY and NVO trade at premium valuations — any clinical setback or guidance miss is severely punished
- Payer pushback on GLP-1 reimbursement remains a headwind to penetration in commercial insurance
- Supply chain execution risk — manufacturing at GLP-1 scale requires billions in new plant investment
- Long-term safety data is still accumulating; any unexpected adverse finding would be market-moving
Prefer passive exposure to this theme? These ETFs provide broad coverage without individual stock selection.
Frequently Asked Questions
What are GLP-1 stocks?+
GLP-1 stocks are shares in pharmaceutical companies developing or manufacturing GLP-1 receptor agonist drugs — the class of medications that includes Ozempic, Wegovy, Mounjaro, and Zepbound. These drugs treat obesity, type 2 diabetes, and increasingly, cardiovascular and metabolic conditions.
Is Eli Lilly or Novo Nordisk the better GLP-1 investment?+
Both LLY and NVO are leading GLP-1 stocks. Lilly's tirzepatide (dual GLP-1/GIP agonist) demonstrates superior weight loss efficacy. Novo Nordisk's semaglutide has a longer commercial track record and broader cardiovascular outcome data. Valuation, pipeline depth, and manufacturing capacity are key differentiators.
Sign in to BriMindInvest to compare any two stocks with live metrics, AI scores, valuation charts, and personalised insights.